Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effects of resveratrol dimer from melinjo (Gnetum gnemon) on the adiponectin and its-related molecules among healthy adult males

Randomized, double-blind, placebo-controlled parallel-group comparative study to evaluate the effects of resveratrol dimer from melinjo (Gnetum gnemon) on the adiponectin and its-related molecules among healthy adult males - Comparative study to evaluate the efficacy of melinjo among healthy volunteer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000025643

Enrollment

Registered

2017-04-01

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

Melinjo 300mg group: Melinjo at 300mg/day (melinjo tablet 150mg 2 tablet with single daily dosing during 2 weeks) Melinjo 150mg group: Melinjo at 150mg/day (melinjo tablet 75mg 2 tablet with singl

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Healthy, non-smoking Japanese male volunteers

Exclusion criteria

Exclusion criteria: 1) An allergy to melinjo and any medicine or food 2) A history of any infectious disease with in 4 weeks before enrolment 3) The use of any investigational drugs within 3 months 4) The use of melinjo or medicines within 2 weeks before enrolment 5) The use of prescription or over-the-counter medications or alcohol within 2 days before enrolment 6) Consumption of functional foods related to lipid and glucose metabolism 7) Regularly drinking red wine 8) Preexisting liver, renal, lung, gastrointestinal tract or heart disease

Design outcomes

Secondary

Measure	Time frame
DsbA-L mRNA PPAR activity and mRNA Adiponectin activity HMW adiponectin activity	—

Primary

Measure	Time frame
The effects of melinjo seed extract administration for 2 weeks on the DsbA-L activity	—

Countries

Japan

Contacts

Public ContactKentaro Oniki

Graduate School of Pharmaceutical Sciences, Kumamoto University Division of Pharmacology and Therapeutics

oniken@kumamoto-u.ac.jp096-371-4512

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026